How Epigenetic Marks Drive Cancer Stem Cells and New Therapeutic Targets
A comprehensive review reveals how DNA and histone modifications sustain cancer stem cell self-renewal, therapy resistance, and tumor propagation.
Summary
This landmark review from Galassi et al. (2025) examines how epigenetic mechanisms—including DNA methylation, histone acetylation, methylation, and ubiquitination—govern cancer stem cell (CSC) identity across AML, CML, glioblastoma, colorectal cancer, and breast cancer. CSCs are a small, poorly differentiated tumor subpopulation capable of self-renewal, generating differentiated progeny, and resisting therapy. The authors detail how enzymes such as DNMT1, TET2, EZH2, and HDACs maintain stemness programs while suppressing differentiation. Crucially, CSC epigenomes share features with embryonic stem cells rather than adult stem cells. The review also critically evaluates clinical-stage epigenetic drugs—DNMT inhibitors, HDAC inhibitors, EZH2 inhibitors—as strategies to eradicate CSCs, noting both promise and significant challenges including plasticity-driven resistance.
Detailed Summary
Cancer stem cells (CSCs) are a rare, poorly differentiated subpopulation within tumors that can self-renew indefinitely, repopulate the tumor mass, and resist standard therapies. While genetic mutations have long been viewed as the primary drivers of CSC identity, this comprehensive 2025 review by Galassi, Manic, Esteller, Galluzzi, and Vitale argues compellingly that reversible epigenetic mechanisms are equally—if not more—central to establishing and maintaining CSC properties.
The review systematically covers three major layers of epigenetic regulation. First, DNA methylation: DNMT1 is shown to be uniquely required for CSC survival (but not normal stem cells) across AML, breast cancer, and CRC, silencing differentiation genes and tumor suppressors. TET2 loss-of-function mutations—common in AML—cause widespread hypermethylation of hematopoietic differentiation genes, expanding leukemia stem cells (LSCs). IDH1/IDH2 mutations produce the oncometabolite D-2-hydroxyglutarate, which inhibits TET enzymes and drives hypermethylation, further locking cells in a stem-like state. Second, histone methylation: polycomb repressive complexes (PRC1/PRC2) silence differentiation genes via H3K27me3 deposition by EZH2, while aberrant H3K4me3 activity through MLL fusion proteins drives LSC expansion in leukemia. Bivalent chromatin domains—co-marked by activating H3K4me3 and repressive H3K27me3—keep lineage genes poised for rapid activation, a feature shared between CSCs and embryonic stem cells. Third, histone acetylation and ubiquitination: HDACs suppress differentiation and apoptosis, while BRD4 and other bromodomain proteins amplify stemness transcriptional programs at super-enhancers.
Key oncogenic pathways—WNT/β-catenin, NOTCH, Hedgehog, and HOX gene clusters—are epigenetically activated in CSCs, while tumor suppressor pathways are silenced. The review also highlights that CSC plasticity (the reversible interconversion between stem-like and differentiated states) is itself epigenetically encoded, enabling bulk tumor cells to re-acquire stemness under stress—a major source of therapy resistance.
Therapeutically, the authors critically evaluate DNMT inhibitors (azacitidine, decitabine), HDAC inhibitors (vorinostat, romidepsin), EZH2 inhibitors (tazemetostat), BET bromodomain inhibitors, and LSD1/KDM inhibitors. While several are FDA-approved (largely for hematological malignancies), their efficacy against solid tumor CSCs remains limited. Combination strategies targeting multiple epigenetic axes simultaneously, or pairing epigenetic drugs with immunotherapy or differentiation-inducing agents, are highlighted as the most promising directions.
A key conceptual contribution is the authors' emphasis that epigenetic targeting of CSCs must account for tumor heterogeneity and plasticity: eliminating epigenetically defined CSC pools may be undermined if non-CSC cells can epigenetically revert to a stem-like state. Future precision strategies will need to integrate single-cell epigenomic profiling to map CSC-specific vulnerabilities.
Key Findings
- DNMT1 is uniquely required for CSC survival—not normal stem cells—across leukemia, breast cancer, and colorectal cancer.
- TET2 mutations and IDH1/IDH2 oncometabolites drive DNA hypermethylation that locks leukemia stem cells in a self-renewing state.
- EZH2-mediated H3K27me3 and bivalent chromatin domains keep differentiation genes silenced in CSCs, mirroring embryonic stem cell epigenomes.
- Cancer stem cell plasticity—epigenetically encoded reversible interconversion between stem and non-stem states—is a major driver of therapy resistance.
- Combination epigenetic therapies targeting multiple chromatin axes show the greatest preclinical promise for CSC eradication.
Methodology
This is a comprehensive narrative review drawing on preclinical studies, genomic and epigenomic profiling datasets, and clinical trial data across AML, CML, glioblastoma, colorectal cancer, and breast cancer. The authors synthesize mechanistic findings from in vitro models, mouse xenograft and orthotopic tumor models, and patient-derived CSC lines. No original experimental data were generated.
Study Limitations
As a review, the paper does not present new experimental evidence, and many mechanistic claims rely on preclinical models that may not fully recapitulate human tumor biology. The high plasticity of CSCs means that even successful epigenetic targeting may be circumvented by non-CSC populations reverting to stemness, a challenge not yet fully resolved by current therapeutic approaches.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.